Philips announced EUR 4.4 billion in sales for the second quarter of 2024, representing a 4% rise in comparable growth. The company's adjusted EBITA margin hit 16.4%, aided by a US tariff refund.
The 4.2% margin boost from US tariff refunds
A significant portion of Philips' profitability in the second quarter was driven by a one-time financial windfall rather than purely operational gains. According to the company's report,a US tariff refund provided an effective 4.2% boost to the group's adjusted EBITA margin. this benefit was critical in maintaining the headline figure of 16.4%.
Without this specific refund, the company's Diagnosis & Treatment segment would have seen its adjusted EBITA margin decline.. while the segment reported a 13.9% margin including a 4.6% tariff benefit, the company noted that excluding that benefit, margins actually decreased due to the combined pressures of cost inflation, higher tariffs, and unfavorable mix effects.
Personal Health leads with 8% comparable sales growth
The Personal Health division emerged as the primary driver of volume growth during this period. This segment recorded 8% comparable sales growth and achieved an adjusted EBITA margin of 23.0%, which included a 5.0% benefit from the US tariff refund. Even when stripping away the refund, the segment saw rising margins due to increased sales and productivity measures that helped offset inflation.
Other business units shwed more modest momentum. Both the Diagnosis & Treatment and Connected Care segments reported 2% comparable sales growth. While Connected Care saw an adjusted EBITA margin of 17.8% (including a 6.1% tariff benefit), its underlying operational improvements were primarily used to mitigate the rising costs of tariffs and inflation.
AI-driven Titanion MR and radiation-reducing SmartIQ tech
Philips is attempting to pivot toward high-margin innovation to secure long-term growth. The company recently unveiled the Titanion MR, an AI-powered 3.0T MRI system designed for ultra-high-gradient performance. This move signals a deeper integration of artificial intelligence into the company's core medical imaging hardware.
Further technological advancements include the SmartIQ platform for the Azurion image-guided therapy system. This technology is designed to address the clinical trade-off between image quality and radiation exposure during coronary procedures. Philips claims the SmartIQ ultra-low dose protocol can use over 50% less X-ray radiation than current low-dose settings, a claim supported by the company's first published clinical evidence.
Scaling hospital networks from Poland to the UK
Global expansion remains a core pillar of the Philips strategy, with significant recent activity in European healthcare markets. In Poland, the company is working to modernize more than 200 hospitals through over 300 technology projects funded by the country's National Recovery and Resilience Plan. This large-scale deployment focuses on imaging and patient monitoring solutions.
In the United Kingdom, Philips has entered into a long-term enterprise imaging partnership with the Imperial College Healthcare NHS Trust. Additionally, the company was selected to support a hospital-at-home initiative for Region Stockholm via Karolinska University Hospital. This program aims to provide remote patient monitoring and AI-enabled services for up to 15,000 patients annually .
The impact of shifting North American order timing
Several uncertainties remain regarding the company's ability to maintain this trajectory in the coming months. While CEO Roy Jakobs stated that customer demand for innovations remains healthy, he admitted that certain large orders in North America have shifted from the second quarter into the third quarter. This timing shift makes it difficult to assess the immediate strength of the North American market.
Furthermore, the heavy reliance on the US tariff refund raises questions about the sustainability of current profit levels. because the refund significantly padded the adjusted EBITA, it remains to be seen whether Philips can maintain its increased profit guidance through organic productivity gains alone if cost inflation and tariff pressures continue to weigh on the Diagnosis & Treatment and Connected Care segments.
Comments 0